Current Melanoma Treatments: Where Do We Stand?

Area of Science:

• Immunology
• Cancer Biology
• Medical Oncology

Background:

• Recent decades have seen significant advancements in immunology and cancer biology.
• Novel therapeutics, including immune checkpoint inhibitors and targeted therapies, have revolutionized metastatic melanoma treatment.

Purpose of the Study:

• To review the current landscape of metastatic melanoma therapeutics.
• To discuss the evolving role of neoadjuvant versus adjuvant therapy.
• To address challenges in managing treatment resistance and novel immunotherapy interventions, especially for non-cutaneous melanoma.

Main Methods:

• Review of updated clinical trial data.
• Analysis of survival curves and recurrence-free survival rates.
• Discussion of emerging therapeutic strategies and challenges.

Main Results:

• Immune checkpoint inhibitors and targeted therapies demonstrate efficacy in metastatic and adjuvant settings.
• Evidence suggests high recurrence-free survival rates with neoadjuvant therapy.
• Plateau effects on survival curves are observed with current treatments.

Conclusions:

• Current immunotherapies and targeted therapies have significantly improved outcomes for metastatic melanoma.
• The choice between neoadjuvant and adjuvant therapy requires further investigation.
• Managing treatment resistance and exploring novel immunotherapies are critical future directions for melanoma treatment, particularly non-cutaneous forms.